GHRP-6

GHRP-6

GHRP-6 Alias: GHRP-6; [HIS1, LYS6]-GHRP; HIS-D-TRP-ALA-TRP-D-PHE-LYS-NH2; H-HIS-D-TRP-ALA-TRP-D-PHE-LYS-NH2 GHRP-6 Unit Size: 5 mg/vial GHRP-6 Unit Quantity: 1 Vial GHRP-6 Synonyms:GHRP-6 Acetate GHRP-6 Sequence:H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 GHRP-6 CAS: 87616-84-0 GHRP-6 M.F.: C46H56N12O6 GHRP-6 M.W.: 873.01 GHRP-6 Purity (HPLC): 98.0%min.

GHRP-6 Appearance: White powder GHRP-6 Single Impurity (HPLC): 1.0%max GHRP-6 Amino Acid Composition: ±10% of theoretical GHRP-6 Peptide Content (N%): ≥80.0% GHRP-6 Water Content(Karl Fischer): ≤6.0% GHRP-6 Acetate Content (HPIC): ≤12.0% GHRP-6 MS(ESI): Consistent GHRP-6 Mass Balance: 95.0~105.0% GHRP-6 storage temp.:?20°C GHRP-6 Identity (ESI-MS):873.01±1.0 GHRP-6 Source:Chemical Synthesis GHRP-6 Storage:Lyophilized Fragment GHRP-6 is stable at room temperature for 90 days,however it should be stored in a freezer below -8C for any extended period of time.

After reconstituting GHRP-6 should be refrigerated at temperatures not to exceed 36 F. Terms The products we offer are intended for laboratory research use only. Please familiarize yourself with our Terms of Service prior to ordering.

(GHRP-6) (developmental code name SKF-110679), also known as GHRP-6releasing hexapeptide, is one of several synthetic met-enkephalin analogues that include unnatural D-amino acids, were developed for theirGHRP-6releasing activity and are called GHRP-6 secretagogues. They lack opioid activity but are potent stimulators of GHRP-6 (GH) release.

These secretagogues are distinct from GHRP-6 releasing hormone (GHRH) in that they share no sequence relation and derive their function through activation of a completely different receptor.

This receptor was originally called the GHRP-6secretagogue receptor (GHSR), but due to subsequent discoveries, the hormone ghrelin is now considered the receptor's natural endogenous ligand, and it has been renamed as the ghrelin receptor. Therefore, these GHSR agonists act as synthetic ghrelin mimetics.

It has been discovered that when GHRP-6 and insulin are administered simultaneously, GH response to GHRP-6 is increased (1). However, the consumption of carbohydrates and/or dietary fats, around the administration window of GH secretagogues significantly blunts the GH release.

A recent study in normal mice showed significant differences in body composition, muscle growth, glucose metabolism, memory and cardiac function in the mice being administered the GHRP-6 (2).

There are still many questions regarding this fairly new compound, scientists are hoping to gain a better clinical understanding of the peptide through further research over the next few years.

GH secretagogues differ from exogenous rh-g-h in their effects primarily due to the fact that endogenous GH contains all five isoforms of GHRP-6, whereas exogenous GH contains only the 20 kilodalton isoform. Different isoforms affect tissues in discreet ways that the 20 kDa isoform cannot.

Administration of GH secretagogues causes a pulse-release of GH from the pituitary which is cleared from the body within a few hours. This does not significantly raise plasma insulin-like growth factor 1 (IGF-1) levels.